Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension trial to NN1250-3579 comparing NN1250 versus insulin glargine over 104 weeks
2009-015754-38Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Feb 2010
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of insulin degludec in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Treatment-emergent adverse events. Started Feb 2010; status: completed.
02
Drugs
insulin degludec
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2009-015754-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015754-38.